[1]
O. S. Sibanda, “Comparative analysis of access to patented HIV/AIDS pharmaceutical medicines through the Canadian and EU TRIPS flexibilities measures: are they efficacious or overly burdensome and ineffective measures?”, PER, vol. 15, no. 2, pp. 520–552, May 2017, doi: 10.17159/1727-3781/2012/v15i2a2498.